Stoke Therapeutics Inc

NASDAQ:STOK   10:57:57 AM EDT
11.72
+0.16 (+1.38%)
Earnings Announcements

Stoke Therapeutics Inc - Cash Runway Anticipated To Fund Operations Into 2025

Published: 05/10/2022 11:26 GMT
Stoke Therapeutics Inc (STOK) - Stoke Therapeutics Inc - Cash Runway Anticipated to Fund Operations Into 2025.
Stoke Therapeutics Inc - Qtrly Loss per Share $0.66.
Revenue is expected to be $2.64 Million
Adjusted EPS is expected to be -$0.69

Next Quarter Revenue Guidance is expected to be $3.23 Million
Next Quarter EPS Guidance is expected to be -$0.71

More details on our Analysts Page.